BACKGROUND AND PURPOSE: The choline (Cho)/creatine (Cr) ratio has been shown to be a reliable proton MR spectroscopy metabolic marker for differentiating squamous cell carcinoma (SCCA) from normal muscle in the upper aerodigestive tract. However, it is unclear whether the Cho/Cr ratio can be used to differentiate a malignant tumor from a benign neoplasm in the extracranial head and neck. Our purpose was to determine whether the Cho/Cr ratio can be used to differentiate benign from malignant tumors in this region. METHODS: In vitro one-dimensional proton MR spectroscopy (2,000/136,272 [TR/TE]) was performed at 11 T on tissue specimens obtained from glomus tumors (n = 3), inverting papilloma (n = 1), and schwannoma (n = 1). Cho/Cr area ratios were calculated and compared with similar, previously reported in vitro (11 T) findings and with samples of SCCA and normal muscle. RESULTS: The Cho/Cr ratio was elevated in relation to muscle in all benign tumors at TE = 136 (glomus tumors = 4.52, inverting papilloma = 3.85, schwannoma = 2.2) and at TE = 272 (glomus tumors = 8.01, inverting papilloma = 2.1, schwannoma = 4.28). The average Cho/Cr ratio for benign lesions was 3.92 (TE = 136) and 6.11 (TE = 272). The Cho/Cr ratio was significantly higher in benign tumors than in both SCCA and muscle. The average Cho/Cr ratio for muscle at TEs of 136 and 272 was 1.16 and 1.31, respectively, whereas for SCCA the average Cho/Cr ratio at TEs of 136 and 272 was 1.67 and 2.45, respectively. CONCLUSION: In our small group, the Cho/Cr ratio was significantly higher in benign tumors than in muscle and SCCA of the extracranial head and neck.
BACKGROUND AND PURPOSE: The choline (Cho)/creatine (Cr) ratio has been shown to be a reliable proton MR spectroscopy metabolic marker for differentiating squamous cell carcinoma (SCCA) from normal muscle in the upper aerodigestive tract. However, it is unclear whether the Cho/Cr ratio can be used to differentiate a malignant tumor from a benign neoplasm in the extracranial head and neck. Our purpose was to determine whether the Cho/Cr ratio can be used to differentiate benign from malignant tumors in this region. METHODS: In vitro one-dimensional proton MR spectroscopy (2,000/136,272 [TR/TE]) was performed at 11 T on tissue specimens obtained from glomus tumors (n = 3), inverting papilloma (n = 1), and schwannoma (n = 1). Cho/Cr area ratios were calculated and compared with similar, previously reported in vitro (11 T) findings and with samples of SCCA and normal muscle. RESULTS: The Cho/Cr ratio was elevated in relation to muscle in all benign tumors at TE = 136 (glomus tumors = 4.52, inverting papilloma = 3.85, schwannoma = 2.2) and at TE = 272 (glomus tumors = 8.01, inverting papilloma = 2.1, schwannoma = 4.28). The average Cho/Cr ratio for benign lesions was 3.92 (TE = 136) and 6.11 (TE = 272). The Cho/Cr ratio was significantly higher in benign tumors than in both SCCA and muscle. The average Cho/Cr ratio for muscle at TEs of 136 and 272 was 1.16 and 1.31, respectively, whereas for SCCA the average Cho/Cr ratio at TEs of 136 and 272 was 1.67 and 2.45, respectively. CONCLUSION: In our small group, the Cho/Cr ratio was significantly higher in benign tumors than in muscle and SCCA of the extracranial head and neck.
Authors: S K Mukherji; A A Mancuso; I M Kotzur; W M Mendenhall; P S Kubilis; R P Tart; W R Lee; D Freeman Journal: Radiology Date: 1994-10 Impact factor: 11.105
Authors: H G Krouwer; T A Kim; S D Rand; R W Prost; V M Haughton; K C Ho; S S Jaradeh; G A Meyer; K A Blindauer; J F Cusick; G L Morris; P R Walsh Journal: AJNR Am J Neuroradiol Date: 1998-10 Impact factor: 3.825
Authors: W G Negendank; T R Brown; J L Evelhoch; J R Griffiths; L A Liotta; A R Margulis; J D Morrisett; B D Ross; F Shtern Journal: Radiology Date: 1992-12 Impact factor: 11.105
Authors: M C Preul; Z Caramanos; D L Collins; J G Villemure; R Leblanc; A Olivier; R Pokrupa; D L Arnold Journal: Nat Med Date: 1996-03 Impact factor: 53.440
Authors: Tedros Bezabeh; Olva Odlum; Richard Nason; Paul Kerr; Donna Sutherland; Rakesh Patel; Ian C P Smith Journal: AJNR Am J Neuroradiol Date: 2005-09 Impact factor: 3.825
Authors: Ann D King; David K W Yeung; Anil T Ahuja; S F Leung; Gary M K Tse; Andrew C van Hasselt Journal: AJNR Am J Neuroradiol Date: 2004-03 Impact factor: 3.825
Authors: Sotirios Bisdas; Sebastian Fetscher; Alfred C Feller; Mehran Baghi; Rainald Knecht; Wolfgang Gstoettner; Thomas J Vogl; Jörn O Balzer Journal: Eur Arch Otorhinolaryngol Date: 2007-05-04 Impact factor: 3.236